AIT Therapeutics Receives Patent Allowance for Delivery of Inhaled Nitric Oxide at Concentrations of at Least 160ppm for Treatment of Bronchiolitis in Infants

AIT Therapeutics (OTC:AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced the allowance of its European Patent Application Number 13757959.5 entitled: “Inhalation of Nitric Oxide for Treating Respiratory Diseases.”  The patent claims, directed towards the treatment of infants suffering from bronchiolitis with intermittent inhalation of at least 160ppm gaseous NO, are covered through March 7, 2033.

As quoted in the press release:

“We are pleased to continue to strengthen our intellectual property portfolio with the addition of this patent covering the delivery of NO at a concentration of at least 160ppm for infants with bronchiolitis,” said Steven Lisi, Chairman and Chief Executive Officer of AIT Therapeutics.  “The patent covers use in the treatment of bacterial, viral, and/or fungal bronchiolitis, which includes RSV, the leading cause of bronchiolitis.  Importantly, the patent also covers the intermittent delivery of NO, as precisely described in the protocol of our ongoing bronchiolitis (NO-BRO) trial.  We continue to anticipate top-line data from the NO-BRO trial by the end of this quarter.”

Click here to read the full press release.